Abstract:Copper is an essential trace metal for biological processes in humans and animals. A low level of copper detection at physiological pH using fluorescent probes is very important for in vitro applications, such as the detection of copper in water or urine, and in vivo applications, such as tracking the dynamic copper concentrations inside cells. Copper homeostasis is disrupted in neurological diseases like Alzheimer's disease, and copper forms aggregates with amyloid beta (Ab42) peptide, resulting in senile plaques in Alzheimer's brains. Therefore, a selective copper detector probe that can detect amyloid beta peptide-copper aggregates and decrease the aggregate size has potential uses in medicine. We have developed a series of Cu2+-selective low fluorescent to high fluorescent tri and tetradentate dentate ligands and conjugated them with a peptide ligand to amyloid-beta binding peptide to increase the solubility of the compounds and make the resultant compounds bind to Cu2+–amyloid aggregates. The copper selective compounds were developed using chemical scaffolds known to have high affinity and selectivity for Cu2+, and their conjugates with peptides were tested for affinity and selectivity towards Cu2+. The test results were used to inform further improvement of the next compound. The final Cu2+ chelator–peptide conjugate we developed showed high selectivity for Cu2+ and high fluorescence properties. The compound bound 1:1 to Cu2+ ion, as determined from its Job's plot. Fluorescence of the ligand could be detected at nanomolar concentrations. The effect of this ligand on controlling Cu2+–Ab42 aggregation was studied using fluorescence assays and microscopy. It was found that the Cu2+–chelator–peptide conjugate efficiently reduced aggregate size and, therefore, acted as an inhibitor of Ab42-Cu2+ aggregation. Since high micromolar concentrations of Cu2+ are present in senile plaques, and Cu2+ accelerates the formation of toxic soluble aggregates of Ab42, which are precursors of insoluble plaques, the developed hybrid molecule can potentially serve as a therapeutic for Alzheimer's disease.

A Copper–amyloid-Β Targeted Fluorescent Chelator As a Potential Theranostic Agent for Alzheimer's Disease

Specific Self-Monitoring of Metal-Associated Amyloid-Β Peptide Disaggregation by a Fluorescent Chelator

A Copper-Selective Sensor and Its Inhibition of Copper-Amyloid Beta Aggregation

Light-controlled Fluorescent Probes for Precisely Monitoring Brain Amyloid-Β Aggregates in Alzheimer's Disease

A Novel Viscosity Sensitive Hemicyanine Fluorescent Dye for Real-Time Imaging of Amyloid-Β Aggregation

Multifunctional Fluorescence Sensor As a Potential Theranostic Agent Against Alzheimer's Disease.

Sensitive Imaging and Effective Capture of Cu2+: Towards Highly Efficient Theranostics of Alzheimer's Disease

Design and Synthesis of Curcumin Analogues for in Vivo Fluorescence Imaging and Inhibiting Copper-Induced Cross-Linking of Amyloid Beta Species in Alzheimer's Disease.

High-fidelity imaging of amyloid-beta deposits with an ultrasensitive fluorescent probe facilitates the early diagnosis and treatment of Alzheimer's Disease

Multifunctional Theranostic Carbazole-Based Cyanine for Real-Time Imaging of Amyloid-β and Therapeutic Treatment of Multiple Pathologies in Alzheimer's Disease

Coassembled Chitosan-Hyaluronic Acid Nanoparticles as a Theranostic Agent Targeting Alzheimer's -Amyloid

Design of Self-Assembled Nanoparticles As a Potent Inhibitor and Fluorescent Probe for Β-Amyloid Fibrillization.

N-methylbenzothiazolium based theranostics as fluorescence imaging and photo-oxidation agents for Amyloid-β

Ultrasmall Superparamagnetic Iron Oxide Nanoparticles-Bound NIR Dyes: Novel Theranostic Agents for Alzheimer's Disease

An AIE-active Theranostic Probe for Light-Up Detection of Aβ Aggregates and Protection of Neuronal Cells.

Coassembled Chitosan-Hyaluronic Acid Nanoparticles as a Theranostic Agent Targeting Alzheimer's β-Amyloid

Rational design of a high-affinity fluorescent probe for visualizing monitoring the amyloid β clearance effect of anti-Alzheimer's disease drug candidates

Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

Benzothiazolium Derivative-Capped Silica Nanocomposites for β-Amyloid Imaging In Vivo

Metallosupramolecular complex targeting an α/β discordant stretch of amyloid β peptide

Amyloid-β Deposits Target Efficient Near-Infrared Fluorescent Probes: Synthesis, in Vitro Evaluation and in Vivo Imaging.